Tfc Financial Management Incyte Corp Transaction History

Tfc Financial Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	BUY	$52.16 - $64.19 $730 - $898	14 New	14 $0
Q3 2022 Oct 21, 2022	BUY	$66.18 - $82.86 $39,708 - $49,716	600 New	600 $40,000
Q4 2021 Feb 02, 2022	SELL	$63.34 - $74.11 $316 - $370	-5 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $425 - $548	5 New	5 $0

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Tfc Financial Management, based on Form 13F filings with the SEC.

Stay updated on Tfc Financial Management with notifications on news.